Nextleaf To Launch THC-O As An Excise Tax-Free Alternative To Delta-9-THC
Nextleaf To Launch THC-O As An Excise Tax-Free Alternative To Delta-9-THC
Nextleaf Solutions Ltd. (OTCQB:OILFF) (CSE:OILS) (FSE:L0MA) provided an update on its specialty molecules division, specifically the company's patented novel route of manufacturing D9-tetrahydrocannabinol acetate, colloquially referred to as THC-O.
Nextleaf has recently produced THC-O under the company's Health Canada research license in anticipation of commercialization. Nextleaf has validated its manufacturing process of THC-O through third-party analytical testing.
The company is of the understanding that THC-O is not subject to excise tax as it does not meet the definition of "Total THC" as defined under the Excise Act 2001, which is aligned with the definition of the same in the Cannabis Act.
In Canada, excise tax of a regulated cannabis extract is based on the amount of total delta-9-THC present. Excise tax is a critical issue in the industry, with some cannabis products manufactured with delta-9-THC subject to excise tax over 40% of the duty paid landed cost to provincial government distributors and medical cannabis distributors.
With THC-O, Nextleaf sees potential for market disruption by marketing its novel cannabinoid ingredient as an excise tax-free alternative to delta-9-THC. Nextleaf intends to commercialize the ingredient as a therapeutic product distributed to provincial distributors and medical cannabis sales partners under the company's Health Canada cannabis licenses.
Anecdotally, THC-O products have a more gradual onset, are longer-lasting, and have psychedelic-like effects, as compared to delta-9-THC.
Nextleaf's patented process to manufacture THC-O enables the standardization of a more potent analog of THC. The company holds U.S. and Canadian patents, along with a U.S. patent for a less efficient method to produce THC-O.
Photo by Diyahna Lewis on Unsplash
Related News
Nextleaf Q2 2022 Revenue Grows 774% YoY, Reports Management Changes
Nextleaf Granted U.S. Patent For Technology That Maximizes Cannabinoid Yield & Reduces Waste
Nextleaf Solutions Touts Positive Trends In Gross Margin, Posts $1.15M In Q1 Revenue
Nextleaf Solutions Ltd. (OTCQB:OILFF) (CSE:OILS) (FSE:L0MA) provided an update on its specialty molecules division, specifically the company's patented novel route of manufacturing D9-tetrahydrocannabinol acetate, colloquially referred to as THC-O.
下一葉解決方案有限公司(OTCQB：OILFF)(CSE：OLES)(FSE：L0MA)提供了其特種分子部門的最新情況，特別是該公司獲得專利的新型製造路線D9-四氫大麻酚醋酸酯，俗稱為THC-O.
Nextleaf has recently produced THC-O under the company's Health Canada research license in anticipation of commercialization. Nextleaf has validated its manufacturing process of THC-O through third-party analytical testing.
NextLeaf有最近生產的THC-O根據該公司的加拿大衞生部的研究許可證，預計將進行商業化。NextLeaf已經通過第三方分析測試驗證了其THC-O的製造工藝。
The company is of the understanding that THC-O is not subject to excise tax as it does not meet the definition of "Total THC" as defined under the Excise Act 2001, which is aligned with the definition of the same in the Cannabis Act.
該公司瞭解到THC-O是不需繳納消費税因為它不符合2001年《消費法》所定義的“THC總量”的定義，而2001年消費法的定義與“大麻法”中的定義是一致的。
In Canada, excise tax of a regulated cannabis extract is based on the amount of total delta-9-THC present. Excise tax is a critical issue in the industry, with some cannabis products manufactured with delta-9-THC subject to excise tax over 40% of the duty paid landed cost to provincial government distributors and medical cannabis distributors.
在加拿大，受管制的大麻提取物的消費税是根據存在的三角洲-9-THC總量計算的。消費税是大麻行業的一個關鍵問題，一些用Delta-9-THC生產的大麻產品需要繳納超過支付給省政府經銷商和醫用大麻經銷商的到岸關税的40%。
With THC-O, Nextleaf sees potential for market disruption by marketing its novel cannabinoid ingredient as an excise tax-free alternative to delta-9-THC. Nextleaf intends to commercialize the ingredient as a therapeutic product distributed to provincial distributors and medical cannabis sales partners under the company's Health Canada cannabis licenses.
通過THC-O，NextLeaf看到了市場顛覆的潛力，將其新的大麻類成分作為Delta-9-THC的免税替代品進行營銷。NextLeaf打算將這種成分商業化，作為一種治療產品，根據該公司的加拿大衞生部大麻許可證，分發給各省分銷商和醫用大麻銷售合作伙伴。
Anecdotally, THC-O products have a more gradual onset, are longer-lasting, and have psychedelic-like effects, as compared to delta-9-THC.
坊間傳聞，與Delta-9-THC相比，THC-O產品的起效更緩慢，持續時間更長，並具有迷幻般的效果。
Nextleaf's patented process to manufacture THC-O enables the standardization of a more potent analog of THC. The company holds U.S. and Canadian patents, along with a U.S. patent for a less efficient method to produce THC-O.
NextLeaf製造THC-O的專利工藝使更強大的THC模擬產品實現了標準化。該公司擁有美國和加拿大的專利，以及一種效率較低的生產THC-O方法的美國專利。
Photo by Diyahna Lewis on Unsplash
Diyahna Lewis在Unspash上的照片
Related News
相關新聞
Nextleaf Q2 2022 Revenue Grows 774% YoY, Reports Management Changes
NextLeaf 2022年第2季度收入同比增長774%，報告管理層變化
Nextleaf Granted U.S. Patent For Technology That Maximizes Cannabinoid Yield & Reduces Waste
NextLeaf授予美國最大限度提高大麻產量和減少浪費的技術專利
Nextleaf Solutions Touts Positive Trends In Gross Margin, Posts $1.15M In Q1 Revenue
NextLeaf Solutions吹捧毛利率積極趨勢，公佈第一季度收入115萬美元
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧